LRP6 and breast cancer: Furthermore, treatment of ER− breast cancer cells with pictilisib, a strong PI3Kα/δ and modest PI3Kβ/γ inhibitor, increased mRNA expression of Wnt ligands including WNT2B, WNT3, WNT5B and WNT10A, as well as phosphorylation of LRP6 and β-catenin nuclear translocation [107].